NCT04271488View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 27, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Hepatic Impairment
Interventions
DRUG

Tasurgratinib

Tasurgratinib oral tablet.

DRUG

Tasurgratinib

Tasurgratinib oral capsule.

Trial Locations (6)

Unknown

RECRUITING

Eisai Trial Site #6, Hakata

TERMINATED

Eisai Trial Site #4, Kurume

RECRUITING

Eisai Trial Site #2, Yufu

RECRUITING

Eisai Trial Site #3, Bunkyō-Ku

RECRUITING

Eisai Trial Site #1, Minato-Ku

RECRUITING

Eisai Trial Site #5, Kofu

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY